AND021 is a small molecule drug candidate currently in the preclinical stage.It is developed for th   treatment of HIF-2-dependent renal cell carcinoma.AND021 specifically binds to a pocket in HIF-2α and prevents HIF-2α and HIF-2β from forming transcriptionally functioning HIF-2 complex,thereby downregulating target genes.We developed AND021 internally and currently hold the global rights to its development,manufacture and commercialization.